Table 1.

Healthy volunteer and patient demographics, mean ± standard deviation [range]

Subjects	Sex‡ (M/F)	Age‡ (years)	Body weight	Years since diagnosis	HY‡	Years on LD treatment	LD doses (mg)	CD doses (mg)	Last blood sample (min)
Healthy (Study 1)	9/9	26.0 ± 6.2 [19–46]	71.7 ± 11.3 [59–95]	NA	NA	NA	100 ± 0	25 ± 0	1440 ± 0
Patients (Study 2)	13/5	71.4 ± 6.3 [61–82]	75.4 ± 11.0 [55–96]	9.6 ± 6.7 [2–33]	3.2 ± 0.9 [2–5]	9.5 ± 6.7 [2–33]	275 ± 86.3 [110–410]	68.75 ± 21.6 (27.5–102.5)	285.8 ± 86.3 [180–360]
Healthy (Study 3)	4/6	24.7 ± 4.3 [20–32]	71.3 ± 13.7 [52–100]	NA	NA	NA	300 ± 0†	75 ± 0	810 ± 0

^†Total drug dose administered, dosing interval 2.4 h. ^‡Mean value for adjusted adaptive least absolute shrinkage and selection operator (AALASSO) covariate selection process; sex, 0.389; age, 48.7 years; HY, 1.53. M, male; F, female; LD, levodopa; CD, carbidopa; HY, Hoehn and Yahr stage; NA, not applicable